Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 25,931 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 25,931 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $4,277,837.07. Following the transaction, the chief financial officer now owns 109,665 shares of the company’s stock, valued at approximately $18,091,435.05. This trade represents a 19.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, October 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $126.45, for a total transaction of $235,955.70.
• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $118.21, for a total transaction of $146,343.98.
• On Friday, October 25th, Michael Burkes Brophy sold 691 shares of Natera stock. The shares were sold at an average price of $118.81, for a total transaction of $82,097.71.

Natera Trading Up 2.7 %

Shares of NTRA stock opened at $171.93 on Thursday. The company has a market cap of $22.70 billion, a PE ratio of -97.69 and a beta of 1.65. Natera, Inc. has a 1 year low of $62.96 and a 1 year high of $183.00. The stock’s 50 day simple moving average is $165.35 and its two-hundred day simple moving average is $135.41. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same period in the prior year, the firm posted ($0.95) EPS. The firm’s revenue was up 63.9% compared to the same quarter last year. Research analysts predict that Natera, Inc. will post -1.61 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Canaccord Genuity Group raised their price target on Natera from $165.00 to $180.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Sanford C. Bernstein lifted their target price on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. Robert W. Baird upped their price target on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Piper Sandler increased their price objective on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. Finally, Leerink Partners boosted their target price on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $160.63.

Institutional Investors Weigh In On Natera

Institutional investors and hedge funds have recently modified their holdings of the business. Blue Trust Inc. increased its stake in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Quarry LP increased its stake in Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after buying an additional 190 shares during the period. Versant Capital Management Inc lifted its holdings in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after buying an additional 166 shares in the last quarter. Covestor Ltd lifted its holdings in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares during the period. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.